full
border
#666666
http://www.lennonsearch.com/wp-content/themes/smartbox-installable/
http://www.lennonsearch.com/
#26ADE4
style3
Over 25 Years Of Expertise
828-403-6096

Archive for April, 2014

28
Apr

Just two months after raising $84 million from an upsized IPO, Concert Pharmaceuticals says that a key Phase II study of its lead drug–CTP-499–flopped on its primary endpoint for diabetic kidney disease. …read more Source: On heels of an IPO, Concert’s kidney drug flops in PhII     

28
Apr

Shares of OncoGenex went into meltdown mode this morning after the biotech and its partner Teva put out word that their experimental prostate cancer drug had flunked a long-awaited Phase III study. Shares of OncoGenex immediately shed more than half their value in the reckoning with investors. …read more Source: OncoGenex, Teva flag a failed […]

28
Apr

Furiex has landed its big buyout deal. After Furiex nabbed promising late-stage data on a new drug for irritable bowel syndrome and virtually slapping a “for sale” sign on the company, Forest Labs has swooped in to buy the biotech company for $1.1 billion and potentially $360 million in contingent value rights. …read more Source: […]

default
Loading posts...
link_magnifier
#5C5C5C
off
fadeInDown
loading
#5C5C5C
off